FFRangio System vs Reveal LINQ
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
The FFRangio System is designed for real-time, wire-free FFR guidance to optimize percutaneous coronary intervention (PCI) decisions for patients with coronary artery disease. In contrast, the Reveal LINQ is an implantable cardiac monitor that continuously records ECG to detect and diagnose cardiac arrhythmias over an extended period. While both leverage AI in cardiology, their distinct focus areas—coronary artery disease assessment versus long-term arrhythmia detection—make them suitable for different clinical needs.
Choose FFRangio System if…
Choose the FFRangio System if you need real-time, non-invasive functional assessment of coronary artery disease during a cardiac catheterization procedure. This tool is ideal for optimizing percutaneous coronary intervention (PCI) decisions by providing wire-free FFR guidance, lesion impact analysis, and integrated sizing to confirm treatment effectiveness.
View FFRangio System →Choose Reveal LINQ if…
Choose Reveal LINQ if you require long-term, continuous cardiac rhythm monitoring for patients experiencing unexplained syncope, cryptogenic stroke, or suspected paroxysmal atrial fibrillation. This implantable cardiac monitor offers up to three years of ECG recording with AI-powered algorithms to accurately detect and diagnose intermittent arrhythmias that might be missed by shorter-term monitoring methods.
View Reveal LINQ →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | FFRangio System | Reveal LINQ |
|---|---|---|
| Pricing | Contact vendor for pricing information. | Unknown |
| Deployment | SaaS, on-prem, hybrid | The Reveal LINQ ICM is an implantable device placed just beneath the skin in the upper left side of the chest through a small incision. The system includes a MyCareLink™ Monitor, a bedside unit that collects data from the ICM and sends it to the doctor. The Reveal LINQ Mobile Manager app, used by healthcare professionals, is downloaded to an iPad or Android tablet and paired via Bluetooth to a Medtronic patient connector, which communicates with the ICMs. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | FFRangio System | Reveal LINQ |
|---|---|---|
| Name | FFRangio System | Reveal LINQ |
| Description | Delivers wire-free and drug-free 3D FFR guidance, providing accurate multi-vessel FFR results and advanced insights to quickly optimize and confirm PCI decisions for patients with coronary artery disease. | A tiny, implantable cardiac monitor that continuously records ECG for up to three years, utilizing AccuRhythmu2122 AI algorithms to accurately detect and diagnose cardiac arrhythmias, including atrial fibrillation, cryptogenic stroke, and unexplained syncope. |
| Company | CathWorks | Medtronic |
| Key Feature (AI/Algorithm) | Artificial intelligence aids in quick angiogram analysis | AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause) |
| Specialties | Cardiology | Cardiology, Neurology |
Videos
Demos, reviews, and walkthroughs featuring FFRangio System and Reveal LINQ.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
The FFRangio System is designed for real-time, intra-procedural guidance during percutaneous coronary intervention (PCI) in the cath lab, aiding in optimizing treatment decisions for coronary artery disease. In contrast, the Reveal LINQ is an implantable device that provides continuous, long-term ECG monitoring for up to three years to diagnose cardiac arrhythmias, including those associated with cryptogenic stroke and unexplained syncope, outside of the acute procedural setting.
The FFRangio System offers seamless integration with cath lab boom and PACS, which facilitates the transfer of imaging and procedural data. For the Reveal LINQ, data is transmitted wirelessly to the CareLinku2122 network via a patient monitor, and a mobile app is available for clinician device management, suggesting a proprietary data ecosystem that would then require integration with an EHR.
The FFRangio System utilizes artificial intelligence to aid in quick angiogram analysis and provide accurate multi-vessel FFR results for PCI optimization. The Reveal LINQ employs AccuRhythmu2122 AI algorithms specifically designed to accurately detect and diagnose cardiac arrhythmias while significantly reducing false alerts for atrial fibrillation and pauses, thereby preserving sensitivity.
The FFRangio System is primarily suited for interventional cardiologists to guide PCI decisions in patients with coronary artery disease. The Reveal LINQ serves cardiologists and neurologists for long-term monitoring and diagnosis of arrhythmias in patients experiencing atrial fibrillation, cryptogenic stroke, or unexplained syncope.
The FFRangio System features an intuitive user interface, suggesting a potentially straightforward learning process for cath lab staff and physicians. For the Reveal LINQ, the insertion procedure is described as minimally invasive and simplified, but the learning curve would also involve managing data via the mobile app and CareLinku2122 network.
The FFRangio System is ISO 27001 certified for information security, indicating adherence to international standards for managing information security. Medtronic states dedicated protection of patient health data for the Reveal LINQ, acknowledging its role in safeguarding protected health information.
For the FFRangio System, multi-site implementation would involve on-premise deployment and integration with existing cath lab equipment at each site, with time-to-value dependent on installation and staff training. The Reveal LINQ, being an implantable device with a centralized data network (CareLinku2122), would involve training on insertion procedures and managing data across multiple sites via its mobile app, with time-to-value tied to patient enrollment and the duration of continuous monitoring.